A large study showed these SARS-CoV-2 positive groups were more prone to myocarditis, heart failure, arrhythmias, and chest pain—regardless of prior cardiovascular history or presence of congenital heart disease (CHD).

Yael David, PhD, discusses how cccDNA nucleosome positioning drives HBV transcription and how CBL137 disrupts this process to block infection.

ACIP provides recommendations on meningococcal vaccines, RSV vaccination for at-risk adults, and chikungunya vaccines for travelers and laboratory workers, while also addressing safety concerns and potential expansions of use for each.

The Centers for Disease Control and Prevention (CDC) says there are now 7 outbreaks.

Precision BioSciences received the designation for its gene editing therapy, PBGENE-HBV, developed to eliminate the root cause of chronic hepatitis B virus (HBV).

Global study reveals sharp rise in deaths linked to high-risk antibiotic use, prompting urgent calls for stewardship reform and surveillance improvements globally.

In a phase 3 study, GSK’s gepotidacin demonstrated 92% efficacy against the sexually transmitted infection.

To meet ambitious targets for ending the HIV/AIDS epidemic, governments must unite in a global effort to improve access to CD4 testing.

CDC maintains low public health risk despite more cases, the first reported death, and accelerated vaccine development to enhance pandemic preparedness.

The loss of surveillance capabilities complicates efforts to control hepatitis outbreaks, explore new preventive treatments, and support new research trials.

MeMed CEO Eran Eden, PhD, discusses the MeMed BV test and how it can help make the distinction between the types of infections, aid in patient management, and reduce antimicrobial resistance.

Jeff Fischer, MBA, discusses promising preclinical data on a cross-species, cross-strain influenza candidate with pandemic potential at the 2025 Congress of the European Society of
Clinical Microbiology and Infectious Diseases.

A surge in invasive group A Streptococcal (IGAS) infections in children marked by more virulent strains followed a reduction in cases coinciding with protective measures for the pandemic.

National Youth HIV & AIDS Awareness Day emphasizes the urgent need for culturally responsive initiatives, discoveries in hepatitis B and C, FDA fast tracks H5N1 vaccine development, and more.

Carl Schmid, executive director, HIV+Hepatitis Policy Institute, speaks to these closings.

Ross M Boyce, MD, MSc, discusses the diagnostic challenges and the need for greater awareness of tick-borne illnesses in the US, considering their potential severity.

Although there have been decreases in newly reported chronic hepatitis C cases across many demographics, the need to get people screened and given therapy in the same visit remains vital.

Jane E Sykes, BVSc(Hons), PhD, MPH, MBA, discussed how her study revealed a wider geographic distribution of Valley fever, highlighting the need for improved human surveillance.

Study shows benefit using antibiotic earlier in clinical care for gram-negative infections.

A new phase 2 trial raises questions about nirmatrelvir-ritonavir’s broader efficacy, as other studies highlight its effectiveness in reducing mortality among immunocompromised COVID-19 patients.

During these uncertain times, RAIN President and CEO Chelsea Gulden talks about the importance of taking a grassroots approach to HIV advocacy to work with young people in the local communities who are either dealing with the virus or are susceptible to it.

Investigational sa-mRNA vaccine advances to phase 1 trials for pandemic preparedness.

With the Trump administration’s plans to cease funding for Gavi, the Vaccine Alliance, as well as to reduce the US Department of Health and Human Services personnel, public health, both internationally and domestically, is going to be widely affected.

Switching from tenofovir disoproxil fumarate to besifovir dipivoxil maleate improves renal and bone health without compromising antiviral efficacy.

This open-label trial will compare the combination of the company’s therapies, bemnifosbuvir and ruzasvir, with another hepatitis C combination regimen.